AXSM · XBRL financial data

Axsome Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AXSM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	0	—	—	—
Revenue from contracts with customers	—	—	50	271	386	638
Cost of revenue	—	—	5	—	—	—
Research and development	70	58	58	98	187	183
Selling, general and administrative	29	67	159	323	411	571
General and administrative	29	67	25	37	54	63
Total operating expenses	99	125	—	—	—	—
Operating income (loss)	(99)	(125)	(180)	(232)	(281)	(167)
Interest expense	—	—	(10)	(20)	(22)	(16)
Income tax expense (benefit)	0	0	0	1	0	(1)
Net income (loss)	(103)	(130)	(187)	(239)	(287)	(183)
Earnings per share, basic USD per share	(2.77)	(3.47)	(4.60)	(5.27)	(5.99)	(3.68)
Earnings per share, diluted USD per share	(2.77)	(3.47)	(4.60)	(5.27)	(5.99)	(3.68)
Weighted average shares, basic millions of shares	37	38	41	45	48	50
Weighted average shares, diluted millions of shares	37	38	41	45	48	50

Fiscal years (AXSM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	184	86	201	386	315	323
Accounts receivable	—	—	38	95	142	224
Inventory	—	—	4	15	16	28
Prepaid and other current assets	0	0	3	8	12	14
Total current assets	184	87	246	504	485	589
Property and equipment, net	0	0	1	1	1	1
Right-of-use asset	2	1	0	7	5	21
Goodwill	—	—	10	12	12	12
Total assets	186	88	331	588	568	690
Accounts payable	14	13	39	41	72	66
Current portion of long-term debt	—	—	—	—	0	70
Total current liabilities	23	23	97	139	230	379
Long-term debt	48	49	94	178	181	118
Lease liability, non-current	1	—	—	7	6	23
Total liabilities	72	72	222	397	511	602
Accumulated deficit	(279)	(409)	(596)	(836)	(1,123)	(1,306)
Total stockholders' equity	114	16	110	191	57	88
Total liabilities and equity	186	88	331	588	568	690
Common shares outstanding (cover page) millions of shares	37	38	44	47	49	51

Fiscal years (AXSM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(103)	(130)	(187)	(239)	(287)	(183)
Stock-based compensation	15	21	38	63	85	94
Net cash from operating activities	(78)	(108)	(117)	(145)	(128)	(93)
Purchases of property and equipment	0	0	1	1	0	0
Net cash from investing activities	(0)	(0)	(54)	(1)	(0)	(0)
Proceeds from issuing common stock	14	7	237	259	41	68
Proceeds from long-term debt	50	—	—	—	—	—
Repayments of long-term debt	22	—	—	—	—	332
Net cash from financing activities	42	11	285	331	58	101
Net change in cash	(36)	(97)	114	185	(71)	8

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.